Novartis' third-quarter results have exemplified the reason for its recent deal-making activity, as heart failure therapy Entresto finally succumbed to the entry of ...

July 16 (Reuters) - A U.S. federal judge rejected Swiss drugmaker Novartis' (NOVN.S), opens new tab request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of ...

Novartis NOVN-0.27%decrease; red down pointing triangle raised its 2025 outlook after high demand for key drugs drove first-quarter profit and sales above expectations, becoming the first among peers ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug Entresto ...

Novartis (NYSE:NVS) said the U.S. Court of Appeals for the Federal Circuit has upheld the company's U.S. combination patent for its blockbuster cardiac drug Entresto, also known as ...

(RTTNews) - Swiss drug major Novartis (NVS) Monday announced that the US Court of Appeals for the Federal Circuit or CAFC has decided to upheld the validity of the ...

“As we have long recognized, ‘[t]he invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” – CAFC opinion The U.S. Court of Appeals for the Federal Circuit (CAFC) ...

Novartis wasn't successful in convincing a U.S. appeals court to stop MSN Pharmaceuticals' proposed generic of Novartis' Entresto, per a Reuters report. The U.S. Court of Appeals for the Federal ...

Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...